BAP1突变和多叶膜间皮瘤:遗传见解,临床影响和治疗前景
Susana Cedres1, Augusto Valdivia1, Ilaria Priano1
1Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Universitari, Paseo Vall d'Hebron 119, 08035 Barcelona, Spain.
Cancers
|May 14, 2025
概括
腹半径质瘤 (PM) 是一种与石棉有关的癌症. 虽然BAP1基因变异在PM中很常见,但其作为临床因素的使用尚未得到当前研究的支持.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 排骨间皮瘤 (PM) 是一种侵袭性恶性瘤,主要是由接触石棉引起的.
- 尽管有监管工作,但PM的发病率在全球范围内正在增加.
- 目前的治疗方法提供了有限的生存益处,需要新的治疗策略.
研究的目的:
- 审查BAP1基因在多间皮瘤中的作用.
- 评估PM患者BAP1变化的预后和预测价值.
- 评估BAP1作为治疗点的潜力.
主要方法:
- 关于研究PM中的BAP1的综合文献综述.
- 分析临床试验数据和PM患者的分子分析.
- 评估与患者预后和治疗反应相关的BAP1突变状态.
主要成果:
- BAP1是PM中最常发生变化的瘤抑制基因.
- 生殖系BAP1突变可能与更好的预后相关,而不是体质突变.
- 针对BAP1缺乏PM的向疗法在早期试验中表现出有限的成功.
结论:
- BAP1是PM的显著分子变化,但缺乏确定的预后或预测价值.
- 矛盾的发现和有限的患者数据排除了BAP1.1的当前临床应用.
- 进一步的研究对于确定BAP1在PM管理中的最终作用至关重要.
相关概念视频
Abnormal Proliferation
4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
The Intrinsic Apoptotic Pathway
6.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
Pleural Disorders: Types and Brief Description
1.1K
The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
1.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84


